# Molecular mechanisms of exercise-induced improvements in Alzheimer’s disease: a focus on lipid homeostasis

**Authors:** Jianfan Zhou, Xianliang Zhang, Shuting Yin, Shuan Xue, Qiang He, Si Chen, Xiangli Xue

PMC · DOI: 10.1186/s40035-026-00537-5 · Translational Neurodegeneration · 2026-03-23

## TL;DR

This paper reviews how exercise can improve Alzheimer’s disease by modulating lipid metabolism, offering a non-drug approach with fewer side effects.

## Contribution

The paper proposes a novel hypothesis that lipids mediate peripheral-central crosstalk between exercise and AD, and explores apolipoprotein E genotype effects.

## Key findings

- Exercise modulates multiple lipids simultaneously, slowing AD progression with minimal side effects.
- Lipids like fatty acids and cholesterol are altered in AD and may serve as early diagnostic and intervention targets.
- Apolipoprotein E genotypes may influence how individuals with AD respond to exercise.

## Abstract

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its pathophysiological mechanisms involve multiple factors, including genomic factors, metabolomic factors, and environmental factors. Lipid dysregulation occurs both centrally and peripherally in patients with AD, and the severity is closely associated with disease progression. Applied studies based on genome-wide association studies, genomic analyses, lipidomic analyses, mass spectrometry, and machine learning, have identified lipids as a key potential target for early diagnosis and intervention in AD. However, due to the complexity of AD pathogenesis and the considerable structural and functional diversities of lipids, pharmacological therapies that target lipid homeostasis have shown limited effectiveness in ameliorating AD pathology and are often accompanied by side effects. In contrast, exercise, a holistic intervention with multitarget effects, can modulate the levels of multiple lipids simultaneously and slow the progression of AD with minimal side effects. However, the mechanisms require further clarification. This review summarizes alterations and mechanisms of action of lipids—including fatty acids, triglycerides, glycerophospholipids, sphingolipids, and cholesterol—in AD and further outlines the possible molecular mechanisms through which exercise influences AD through modulation of lipid metabolism. We also review the recent clinical research on lipid-targeting drugs for AD, and propose a hypothesis that lipids may act as a mediator of the peripheral–central crosstalk between exercise and AD. Additionally, how different apolipoprotein E genotypes may affect the response to exercise in AD is explored. These insights provide a theoretical basis for nonpharmacological interventions for AD and offer an important reference for the development of lipid-related therapeutic targets.

## Linked entities

- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Bnip3 (BCL2 interacting protein 3) [NCBI Gene 84480], Ide (insulin degrading enzyme) [NCBI Gene 15925] {aka 1300012G03Rik, 4833415K22Rik}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, SCD (stearoyl-CoA desaturase) [NCBI Gene 6319] {aka FADS5, MSTP008, SCD1, SCDOS, hSCD1}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, HMGA1 (high mobility group AT-hook 1) [NCBI Gene 3159] {aka HMG-R, HMGA1A, HMGIY}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, Smpd3 (sphingomyelin phosphodiesterase 3, neutral) [NCBI Gene 58994] {aka 4631433G07Rik, Nsm2, fro, nSMase2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 84027], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, ABCC6 (ATP binding cassette subfamily C member 6) [NCBI Gene 368] {aka ABC34, ARA, EST349056, GACI2, MLP1, MOAT-E}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], GSK3A (glycogen synthase kinase 3 alpha) [NCBI Gene 2931], ABCA7 (ATP binding cassette subfamily A member 7) [NCBI Gene 10347] {aka ABCA-SSN, ABCX, AD9}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, Srebf2 (sterol regulatory element binding factor 2) [NCBI Gene 20788] {aka SREBP-2, SREBP2, SREBP2gc, bHLHd2, lop13, nuc}, RXRA (retinoid X receptor alpha) [NCBI Gene 6256] {aka NR2B1, RXR-alpha, RXRalpha}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, Fas (Fas cell surface death receptor) [NCBI Gene 246097] {aka FasR, Tnfrsf6}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Ngf (nerve growth factor) [NCBI Gene 310738] {aka Ngfb, beta-NGF}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Il19 (interleukin 19) [NCBI Gene 329244], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MBTPS1 (membrane bound transcription factor peptidase, site 1) [NCBI Gene 8720] {aka CAOP, PCSK8, S1P, SEDKF, SKI-1}, PSEN1 (presenilin 1) [NCBI Gene 5663] {aka ACNINV3, AD3, CMD1U, FAD, PS-1, PS1}, Bace1 (beta-site APP cleaving enzyme 1) [NCBI Gene 23821] {aka ASP2, Bace}, Adam10 (a disintegrin and metallopeptidase domain 10) [NCBI Gene 11487] {aka 1700031C13Rik, MADM, kuz, kuzbanian}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, FFAR1 (free fatty acid receptor 1) [NCBI Gene 2864] {aka FFA1R, GPCR40, GPR40}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SCARB1 (scavenger receptor class B member 1) [NCBI Gene 949] {aka CD36L1, CLA-1, CLA1, HDLCQ6, HDLQTL6, SR-BI}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, IDE (insulin degrading enzyme) [NCBI Gene 3416] {aka INSULYSIN}, SESN2 (sestrin 2) [NCBI Gene 83667] {aka HI95, SES2, SEST2}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, MFSD2A (MFSD2 lysolipid transporter A, lysophospholipid) [NCBI Gene 84879] {aka HsMFSD2A, MCPH15, MFSD2, NEDMISBA, NLS1, SLC59A1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Mme (membrane metallo endopeptidase) [NCBI Gene 17380] {aka 6030454K05Rik, CALLA, CD10, NEP, SFE}, Abca1 (ATP-binding cassette, sub-family A member 1) [NCBI Gene 11303] {aka ABC-1, Abc1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, GAP43 (growth associated protein 43) [NCBI Gene 2596] {aka B-50, GAP-43, PP46}, Sec24d (SEC24 homolog D, COPII coat complex component) [NCBI Gene 69608] {aka 2310020L09Rik, Gm1349}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** neuroinflammation (MESH:D000090862), lipid metabolism abnormalities (MESH:D052439), neurotoxic (MESH:D020258), Parkinson's disease (MESH:D010300), cognitive decline (MESH:D003072), glucose (MESH:D018149), cytotoxicity (MESH:D064420), neurodegeneration (MESH:D019636), ACH (MESH:D000130), diabetic (MESH:D003920), mitochondrial dysfunction (MESH:D028361), insulin resistance (MESH:D007333), NFTs (MESH:D055956), white matter abnormalities (MESH:D056784), synaptic (MESH:D012183), T2D (MESH:D003924), obese (MESH:D009765), depression (MESH:D003866), nonalcoholic fatty liver disease (MESH:D065626), OA (MESH:D011015), liver tumor (MESH:D008113), hippocampal atrophy (MESH:D001284), AD (MESH:D000544), Lipid (MESH:D011017), amyloid (MESH:C000718787), inflammation (MESH:D007249), traumatic brain injury (MESH:D000070642), memory deficits (MESH:D008569), dementia (MESH:D003704), metabolic disorders (MESH:D008659), amyloid plaques (MESH:D058225), IR (MESH:C537629), PC (MESH:C535298), multiple sclerosis (MESH:D009103), overweight (MESH:D050177), brain atrophy (MESH:C566985)
- **Chemicals:** progesterone (MESH:D011374), SM (MESH:D013109), SP (MESH:C000604007), Lipid (MESH:D008055), TG (MESH:D014280), 25-hydroxycholesterol (MESH:C007997), CER (-), Cholesterol (MESH:D002784), LA (MESH:D019787), MUFA (MESH:D005229), rivastigmine (MESH:D000068836), Ceramide-1-phosphate (MESH:C065576), lactate (MESH:D019344), galantamine (MESH:D005702), fatty acid (MESH:D005227), ALA (MESH:D017962), thiazolidinedione (MESH:C089946), ATP (MESH:D000255), OA (MESH:D019301), eicos-apentaenoic acid (MESH:D015118), PE (MESH:C483858), CE (MESH:D002563), C6-Cer (MESH:C101954), glucose (MESH:D005947), pioglitazone (MESH:D000077205), Glycerophospholipids (MESH:D020404), monoacylglycerol (MESH:D050178), sterols (MESH:D013261), FFA (MESH:D005230), TGs (MESH:C026285), PS (MESH:D010718), Sphingosine-1-phosphate (MESH:C060506), PC (MESH:D010713), memantine (MESH:D008559), PUFA (MESH:D005231), DHA (MESH:D004281), ROS (MESH:D017382), FA (MESH:D005492), MCT (MESH:C000709826), Cer (MESH:D002518), donepezil (MESH:D000077265), bexarotene (MESH:D000077610), glutathione (MESH:D005978), rosiglitazone (MESH:D000077154), Arachidonic acid (MESH:D016718), methamphetamine (MESH:D008694), DAG (MESH:D004075), PA (MESH:D019308), ACH (MESH:D000109), lecanemab (MESH:C000612089), c9,t11-CLA (MESH:C503589), choline alfoscerate (MESH:D005997), lysophosphatidylcholine (MESH:D008244), omega-3 fatty acid (MESH:D015525), Cholesteryl esters (MESH:D002788), Sphingolipids (MESH:D013107), PL (MESH:D010955)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Danio rerio (leopard danio, species) [taxon 7955], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** SK-N-MC — Homo sapiens (Human), Askin tumor, Cancer cell line (CVCL_0530), /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985), Neuro2a — Mus musculus (Mouse), Mouse neuroblastoma, Cancer cell line (CVCL_0470), PC12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13007380/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13007380/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC13007380/full.md

---
Source: https://tomesphere.com/paper/PMC13007380